



Prior Authorization Approval Criteria

Ethyol (amifostine)

Generic name:	amifostine
Brand name:	Ethyol
Medication class:	Organic thiophosphate cytoprotective
FDA-approved uses:	To reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer when the radiation port includes a substantial portion of the parotid glands. To reduce renal toxicity associated with repeated courses of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer.
Usual dose:	Prevention of xerostomia: 200mg/m ² as a 3-minute IV infusion 15 minutes prior to radiation Prevention of renal toxicity: 910mg/m ² as a 15-minute IV infusion 30 minutes prior to chemotherapy

Duration of Therapy: Prior to radiation or chemotherapy

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- Patients undergoing radiation for treatment of head and neck cancer when the radiation port includes a substantial portion of the parotid glands
- OR
- Patients undergoing cisplatin therapy when decreasing the dose of cisplatin or switching to carboplatin is unacceptable

Contraindications: None known.

Not approved if:

- Used for prophylaxis against neutropenia from cyclophosphamide-induced neutropenia (leukopenia), or any alkylating agent. Suggestion of reduction of chemotherapy dose as alternative. If reduction of chemotherapy dose can not be tolerated, use of amifostine can be considered.
- Used for the prophylaxis against thrombocytopenia in patients receiving alkylating agents or carboplatin.
- Used for prophylaxis against neurotoxicity and ototoxicity due to cisplatin or paclitaxel.
- Used in patients who are receiving chemotherapy alone in order to reduce other toxicities.
- Used for prophylaxis against mucositis associated with radiation therapy.
- Patient is hypotensive and cannot stop antihypertensive medications at least 24 hours preceding administration
- Patient is dehydrated

Special issues: Side effects: Hypotension; emesis (give prophylactic antiemetics); monitor calcium levels

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 11/16/04